These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31308720)

  • 1. Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris.
    Farag AGA; Samaka R; Elshafey EN; Shehata WA; El Sherbiny EG; Hammam MA
    Clin Cosmet Investig Dermatol; 2019; 12():497-508. PubMed ID: 31308720
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of CYR61 in psoriatic lesional and perilesional skin: A clinical and immunohistochemical study.
    Shehata WA; Maraee AH; Abdo EE; Hemida AS
    J Cosmet Dermatol; 2021 Sep; 20(9):2981-2988. PubMed ID: 33484099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progranulin and beta-catenin in psoriasis: An immunohistochemical study.
    Farag AGA; Shoaib MA; Samaka RM; Abdou AG; Mandour MM; Ibrahim RAL
    J Cosmet Dermatol; 2019 Dec; 18(6):2019-2026. PubMed ID: 31091001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo.
    Samaka RM; Basha MA; Menesy D
    Clin Cosmet Investig Dermatol; 2019; 12():469-480. PubMed ID: 31303777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plexin-B2 in psoriasis; a clinical and immunohistochemical study.
    Hemida AS; Mareae AH; Elbasiony ASA; Shehata WA
    J Immunoassay Immunochem; 2020 Jul; 41(4):718-728. PubMed ID: 32186222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study.
    Nada HR; El Sharkawy DA; Elmasry MF; Rashed LA; Mamdouh S
    Arch Dermatol Res; 2018 Jan; 310(1):39-46. PubMed ID: 29127481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous JAK Expression in Vitiligo.
    Abdel Motaleb AA; Tawfik YM; El-Mokhtar MA; Elkady S; El-Gazzar AF; ElSayed SK; Awad SM
    J Cutan Med Surg; 2021; 25(2):157-162. PubMed ID: 33174479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Janus kinase signaling pathway in acne lesions.
    Awad SM; Tawfik YM; El-Mokhtar MA; El-Gazzar AF; Abdel Motaleb AA
    Dermatol Ther; 2021 Jan; 34(1):e14563. PubMed ID: 33210790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beclin1 in psoriasis: an immunohistochemical study.
    Amer AS; Samaka RM; Moftah NH
    Clin Exp Dermatol; 2021 Jul; 46(5):851-860. PubMed ID: 33405299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Light chain 3 immunoexpression in psoriasis.
    Samaka RM; Marae A; Faried M; Bazid HAS
    J Immunoassay Immunochem; 2022 Jul; 43(4):365-383. PubMed ID: 34996338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of cornulin in lesional and perilesional skin of plaque psoriasis.
    Shehata WA; Hammam MA; Ayad A; Holah NS
    J Cosmet Dermatol; 2022 Aug; 21(8):3537-3545. PubMed ID: 34859561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor kappa B and cyclo-oxygenase-2: two concordant players in psoriasis pathogenesis.
    Bakry OA; Samaka RM; Shoeib MA; Abdel Aal SM
    Ultrastruct Pathol; 2015 Feb; 39(1):49-61. PubMed ID: 25215902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.
    Andrés RM; Hald A; Johansen C; Kragballe K; Iversen L
    Exp Dermatol; 2013 May; 22(5):323-8. PubMed ID: 23614738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal regulation of fibronectin production by fibroblasts in psoriasis.
    Gubán B; Vas K; Balog Z; Manczinger M; Bebes A; Groma G; Széll M; Kemény L; Bata-Csörgő Z
    Br J Dermatol; 2016 Mar; 174(3):533-41. PubMed ID: 26471375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smad7 in psoriasis vulgaris patients: A clinical and immunohistochemical study.
    Hemida AS; Hammam MA; Salman ATA; Shehata WA
    J Cosmet Dermatol; 2020 Dec; 19(12):3395-3402. PubMed ID: 32307790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Angiogenic Factors in Psoriasis Vulgaris.
    Sankar L; Arumugam D; Boj S; Pradeep P
    J Clin Diagn Res; 2017 Mar; 11(3):EC23-EC27. PubMed ID: 28511390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study.
    Bovenschen HJ; Langewouters AM; van de Kerkhof PC
    Am J Clin Dermatol; 2010; 11(5):343-50. PubMed ID: 20553063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris.
    Alessandrini F; Stachowitz S; Ring J; Behrendt H
    J Invest Dermatol; 2001 Mar; 116(3):394-400. PubMed ID: 11231313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 protein in psoriasis.
    Baran W; Szepietowski JC; Szybejko-Machaj G
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):79-83. PubMed ID: 16200332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesional upregulation of SLURP1 immunostaining parallels disease severity in psoriasis vulgaris patients.
    Assaf M; Salah E
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1329-1337. PubMed ID: 30395407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.